AB0701

COMPARISON OF THE NEW ACR/EULAR CLASSIFICATION CRITERIA OF ANCA-ASSOCIATED VASCULITIS WITH THE EMA ALGORITHM IN CLASSIFICATION OF VASCULITIS

S. Li¹, Q. Zhang². ¹department of Rheumatology and Immunology, Peking University International Hospital; ²department of Rheumatology and Immunology, The First affiliated hospital of Chinese PLA general Hospital, Beijing, China

Objectives: A new set of classification criteria for ANCA-associated vasculitis (AAV) was presented in 2017's ACR annual scientific meeting. In order to evaluate this new set of classification, we conducted the current study to compare it with the EMA's consensus algorithm for classification of systemic vasculitis proposed by Watt et al. in our centre.

Methods: One hundred and twenty-two Chinese patients with clinically diagnosed as AAV in our centre during the past 15 years were retrospectively studied. We compared the new set of ACR/EULAR's classification criteria for AAV, with the EMA's consensus algorithm with surrogate parameters, in the same cohort of patients with primary systemic vasculitis.

Results: Applying the EMA's consensus algorithm with surrogate parameters, the diagnoses were EGPA (n.3), GPA (n.55), microscopic polyangiitis (MPA) (n.47), drug related AAV (n.2), and unclassified (n.5). Using the new ACR/EULAR's classification criteria for AAV, the diagnoses were EGPA (n.8), GPA (n.33), MPA (n.65), overlap with EGPA and GPA (n.2), overlap with GPA and MPA (n.8), and unclassified (n.7) (See the below picture).

Abstract AB0701 – Figure 1

Conclusions: The new 2017 ACR/EULAR classification criteria for AAV and Watts' algorithm were all useful methods to classify patients with systemic vasculitis. The Watts' algorithm can classify all patients into a single category, with more GPA patients, less unclassified patients and without overlapping diagnosis, in comparison, the new 2017 ACR/EULAR classification criteria classified more MPA patients, more unclassified and more overlapping patients.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7593

AB0702

ALKALINE PHOSPHATASE AS A PREDICTOR OF GIANT CELL ARTERITIS – A RETROSPECTIVE ANALYSIS OF CLINICAL FEATURES AND TEMPORAL ARTERY BIOPSY FINDINGS

S. Varier, C. Li. Rheumatology, Royal Surrey County Hospital, Surrey, UK

Background: Giant cell arteritis (GCA) is the most common large vessel vasculitis in the United Kingdom and Northern Europe. Inadequate treatment and delay in diagnosis can lead to a number of devastating consequences.

Objectives: This study looks at whether the presence of a raised alkaline phosphatase (ALP) may aid the diagnosis of GCA, improve the sensitivity of TAB, including in the presence of other proven serum markers and whether it has any correlation with severity of clinical presentation.

Methods: Retrospective multicenter cohort study.

Information was retrospectively gathered on patients who underwent TABs following a clinical working diagnosis of GCA. Only patients who fulfilled the American College of Rheumatology (ACR) classification criteria and had ALP measured within 4 weeks of undergoing TAB were included in the study. Once patients were identified, further information was extrapolated including the values of other serum markers taken, and presenting clinical features.

Results: Our 223 patients sample population who fulfilled the inclusion criteria reflected typical GCA patients: 147 (65.9%) were female and mean age was 73.1 years (SD 10.5). TAB was positive in 54 patients (24.2%). Two patients (3.7%) who had a positive TAB had completely normal serum markers. We were unable

to comment on variables, which could have contributed to this but they likely represented already administered aggressive glucocorticoid treatment at time of serum measurement or atypical presentation of GCA. Raised ALP sensitivity at the current cut off value was very low (14.8%) but with high specificity (90.5%), which was reinforced following ROC curve analysis. Pearson coefficient analysis suggested that there was a weakly associative relationship between raised ALP and degree of clinical suspicion (Correlation 0.346, Sig 0.01)

Conclusions: Patients with a higher level of clinical suspicion and TAB positivity were more likely to have a raised ALP. However, the association strength was weak. ALP is suggested to be highly specific for TAB positivity. The association of raised ALP to degree of clinical features and suspicion of GCA is weak and of low significance, likely a reflection of the limitations of this study. Further robust research may further evaluate this observed relationship.

REFERENCES:

- [1] Yates M, Graham K, Watts RA, MacGregor AJ. The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population. *BMC Musculoskelet Disord*. 172016.
- [2] Ness T, Bley TA, Schmidt WA, Lamprecht P. The Diagnosis and Treatment of Giant Cell Arteritis. *Dtsch Arztebl Int*. 2013;110(21):376–86.
- [3] Nordborg C, Nordborg E, Petrusdottir V. Giant cell arteritis. Epidemiology, etiology and pathogenesis. *Applis*. 2000;108(11):713–24
- [4] Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. *Arthritis Rheum*. 1990;33(8):1122–8.
- [5] Walvick MD, Walvick MP. Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy. *Ophthalmology*. 2011;118(6):1201–4.
- [7] Sheehan NJ. Alkaline phosphatase and gamma-glutamyltransferase in polymyalgia rheumatica and giant cell arteritis. *Ann Rheum Dis*. 1985;44(9):644–5.

Acknowledgements: I would like to acknowledge the involvement of Dr. Sam Norton, MSc supervisor and statistician, Kings College London, Dr. Joe Li and Dr. Alexis Jones with Data collection.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.1571

AB0703

LONG TERM FOLLOW-UP OF BEHÇET'S SYNDROME PATIENTS TREATED WITH CYCLOPHOSPHAMIDE

M. Gurcan¹, S.N. Esatoglu², V. Hamuryudan², C. Saygin³, D. Saygin⁴, S. Ugurlu², E. Seyahi², I. Fresko², M. Melikoglu², S. Yurdakul², H. Yazici², G. Hatemi².

¹Istanbul University, Cerrahpasa Medical School, ²Istanbul University, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; ³Cleveland Clinic, Department of Hematology and Oncology, Taussig Cancer Institute; ⁴Cleveland Clinic, Department of Internal Medicine, Cleveland, USA

Background: Cyclophosphamide (CYC) remains an important treatment option for Behçet's syndrome (BS) patients with life-threatening conditions such as arterial aneurysms. However, several adverse events may occur with CYC and this has led to increased use of biologic agents such as rituximab in other vasculitides.

Objectives: The aim of this study is to delineate the outcome and short and long-term adverse events with CYC use among BS patients.

Methods: We conducted a retrospective chart review of all BS patients treated with oral or intravenous CYC between 1976 and 2006. Patients were called and a standard form was used for collecting demographic characteristics, CYC indication, cumulative dose of CYC and short-term serious adverse events necessitating the cessation of therapy and/or requiring hospitalisation and long-term adverse events (malignancy and infertility), and outcome.

Results: We identified 198 (M/W: 184/14) BS patients who had received CYC. After a median follow up of 17 (IQR: 9–26) years after the initiation of CYC therapy, 52 (26%) patients had died within a median duration of 4^{1–12} years, 33 (17%) were lost after a median follow-up of 9 (3.5–14) years, and 113 (57%) were contacted. CYC was prescribed for vascular involvement in 132 (67%) patients, eye involvement in 52 (26%), central nervous system involvement in 5, both vascular and eye involvement in 7 and both vascular and central nervous system involvement in 2 patients. The median duration of CYC use was 12 (IQR: 4–24) months and median cumulative dose was 13.5 (IQR: 6–49) gr. Among the 52 patients who died, reasons for death were vascular involvement in 26, malignancies in 7, infections in 5 (5 bacterial infections, 1 additional tuberculosis), neurologic involvement in 2, ischaemic stroke in 1, traffic accident in 1, and secondary amyloidosis in 1, esophageal variceal bleeding in 1, and unknown in 5 patients. Sixteen (8%) patients experienced serious adverse events associated with short-term CYC use and 1 of them died due to infection. Among these adverse events, haemorrhagic cystitis occurred in 7 patients, infections in 4 (1/4 died), leukopenia, acute myocardial